dr. mark kris on immunotherapy and frontline options for patients with nsclc
Published 8 years ago • 764 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
1:27
dr. mark g. kris on side effects management with immunotherapies
-
1:28
dr. kris on the future of immunotherapy and targeted therapy in lung cancer
-
1:25
mark kris on new therapies for lung cancer
-
1:36
dr. costin on frontline immunotherapy for patients with nsclc
-
1:39
mark kris, md: choosing a treatment in nsclc
-
1:22
dr. kris on combination chemotherapy approaches in nsclc
-
1:28
dr. kris on sequencing challenges in lung cancer
-
1:36
dr. mark kris discusses dacomitinib for patient with egfr-positive lung cancer
-
0:44
dr. mark kris discusses crizotinib for patients with alk-positive lung cancer
-
1:54
dr. mark kris on the combination of molecularly targeted therapies
-
1:59
dr. kris on adjuvant systemic therapy in nsclc
-
1:17
dr. kris on the challenges of treating lung cancer
-
1:17
dr. kris on personalizing therapy in lung cancer
-
1:45
mark kris, md: lacking actionable mutations in nsclc
-
8:44
upfront immunotherapy for pd-l1 nsclc
-
2:20
dr. kris on the relay trial in egfr nsclc
-
3:53
the potential for adjuvant immunotherapy for nsclc
-
1:49
dr. herbst on the impact of frontline immunotherapy in lung cancer
-
8:46
late-stage trials: immunotherapy combinations for nsclc